Wells Fargo & Company Corbus Pharmaceuticals Holdings, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.11 - $5.46 $529 - $26,295	-4,816 Reduced 1.39%	342,084 $37,000
Q3 2022 Nov 14, 2022	SELL	$0.17 - $5.31 $1 - $31	-6 Reduced -0.0%	346,900 $57,000
Q2 2022 Aug 12, 2022	BUY	$0.21 - $0.53 $16,607 - $41,913	79,083 Added 29.53%	346,906 $88,000
Q1 2022 May 16, 2022	BUY	$0.32 - $0.67 $3,104 - $6,501	9,703 Added 3.76%	267,823 $142,000
Q4 2021 Feb 14, 2022	BUY	$0.6 - $1.11 $4,235 - $7,835	7,059 Added 2.81%	258,120 $158,000
Q3 2021 Nov 15, 2021	BUY	$1.01 - $1.82 $91,402 - $164,706	90,498 Added 56.36%	251,061 $257,000
Q2 2021 Aug 16, 2021	BUY	$1.39 - $2.21 $54,753 - $87,054	39,391 Added 32.51%	160,563 $294,000
Q1 2021 May 13, 2021	BUY	$1.27 - $3.42 $29,180 - $78,581	22,977 Added 23.4%	121,172 $238,000
Q4 2020 Feb 09, 2021	SELL	$0.94 - $1.89 $90,021 - $181,001	-95,768 Reduced 49.37%	98,195 $123,000
Q3 2020 Nov 05, 2020	BUY	$1.5 - $9.38 $30,987 - $193,772	20,658 Added 11.92%	193,963 $349,000
Q2 2020 Aug 13, 2020	BUY	$4.79 - $8.39 $212,810 - $372,750	44,428 Added 34.47%	173,305 $1.45 Million
Q1 2020 May 14, 2020	BUY	$3.44 - $7.21 $443,336 - $929,203	128,877 New	128,877 $675,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.08B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.